Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma
| Status: | Archived |
|---|---|
| Conditions: | Lymphoma |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
A Phase II Study of MGCD0103 (MG-0103) Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma
In this study, MGCD0103, a new anticancer drug under investigation, is given three times
weekly to patients with relapsed and refractory lymphoma.
We found this trial at
2
sites
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
Click here to add this to my saved trials
M. D. Anderson Cancer Center Welcome to UF Health Cancer Center at Orlando Health. For...
Click here to add this to my saved trials